KR
Kausik RaySep 5
Why didn’t achieving an LDL-C of 16mg/dl 6 weeks after MI and an LDL-C difference between groups of 40mg/dl at week 6 with the aforementioned rationale translate into significant clinical benefits at 1 year?
This research is Trending!
View all ESC 2026 trials
LDL Cholesterol Lowering With Evolocumab Before Percutaneous Coronary Intervention for Acute Myocardial Infarction
Key result
Evolocumab before PCI improves 1-year LDL-C target achievement to 82% vs standard care, without reducing events.
- OR 5.54
- 95% CI 4.50-6.82
- P<.001
- n=2,161
Why the trial?
Statin therapy takes weeks to lower LDL cholesterol, leaving early post-infarction risk unaddressed. AMUNDSEN asked whether giving the PCSK9 inhibitor evolocumab immediately before primary PCI for acute myocardial infarction confers additional early benefit over standard lipid-lowering alone.
Does evolocumab started before PCI improve LDL-C control and clinical outcomes at 1 year in patients with high-risk acute MI?
Population
2161 patients with high-risk acute MI undergoing PCI (mean age 67, 79% male)
Comparison
Evolocumab 140 mg SC q2w started before PCI + standard care vs standard care alone
Design
Phase 4 open-label RCT, blinded endpoint adjudication (48 sites, 6 countries)
Follow-up
12 months
Authors
Discussion
1 takeKey questions
Member takes
Where experts stand
Experts agree AMUNDSEN showed evolocumab dramatically improves LDL-C goal attainment after acute MI, but the absence of clinical benefit at one year leaves the field debating whether longer follow-up or better use of existing oral therapies is the real next step.
Cardiologists widely acknowledge the striking lipid-lowering result but note the trial found no reduction in death or cardiovascular hospitalization at one year. The main tension is whether this simply reflects insufficient follow-up time for clinical benefit to emerge, or whether maximizing cheaper oral combination therapy could close most of the gap. The open question is whether longer exposure will eventually translate into fewer events, and whether early PCSK9 inhibitor use can be justified on lipid targets alone.
Agreement
Multiple experts emphasize the same core finding: evolocumab dramatically improved LDL-C goal attainment after acute MI but did not translate into a detectable clinical benefit at one year, suggesting longer follow-up is needed before drawing conclusions about outcomes.
4 clinicians say this directly
Main debate
Is the answer longer PCSK9i follow-up or better use of existing oral combos?
Longer follow-up will show benefit2
Clinical benefit from profound LDL-C lowering requires more time to accrue, consistent with the trajectory of larger PCSK9 inhibitor trials.vs
Maximize oral therapy first1
With less than 30% ezetimibe use in the control arm, cheaper statin-ezetimibe combos could close much of the LDL gap without PCSK9 inhibitors.Not placed5 reporting, watching, or context only
What they’re arguing about
supportiveneutralcautiouscritical
Counts are expert takes we classified by axis. Tap a row to see the takes behind its count.
Still unclear
Whether longer follow-up beyond one year will reveal a clinical event reduction, as several experts expect. Whether maximizing high-intensity statin plus ezetimibe from day one would narrow the LDL-C gap enough to diminish the incremental value of upfront PCSK9 inhibitor therapy. How these results will influence guideline recommendations on the timing and sequencing of lipid-lowering therapies after acute MI.
Key expert perspectives
AMUNDSEN is not 'PCSK9i do not work after MI' but an implementation signal that longer follow-up matters
Cautions against reading the trial as a failure of PCSK9 inhibitors, framing it instead as showing that cath-lab evolocumab produced profound LDL-C lowering without detectable one-year clinical benefit. Highlights that only 3.8% of the standard care arm received a PCSK9 inhibitor and only 40% reached target, calling AMUNDSEN an implementation trial that exposes a real-world treatment gap.
Low ezetimibe use undermines the comparison and cheap oral combos may close the gap
Points out that only about 27% of patients in AMUNDSEN received ezetimibe, arguing that full statin-ezetimibe combination from day one could bring most non-familial hypercholesterolemia patients to target. Notes that in Egypt, where generic combo pills are widely available, roughly 90% of patients are already on high-dose combination therapy.
Ahmed BennisHeart Failure / Cardiomyopathy · Centre Hospitalier Universitaire Hassan IIResults readoutAug 29The clinical hazard ratio is consistent with larger PCSK9 inhibitor outcome trials and supports earlier LDL-C lowering
Frames the result as showing that upfront PCSK9 inhibitor combo therapy dramatically improves LDL-C goal attainment post-ACS. Notes the hazard ratio of 0.94 is consistent with what larger PCSK9 inhibitor trials have shown, implying benefit may emerge with longer exposure.
Distilled from their postX post
Implication
Evolocumab before PCI improves LDL-C targets without reducing 1-year events; challenges acute pleiotropic benefit assumptions and leaves optimal timing open.
Key Points
- To evaluate the efficacy and clinical impact of initiating evolocumab before percutaneous coronary intervention compared with standard care in patients with high-risk acute myocardial infarction.
- International, phase 4, randomized, open-label, blinded-endpoint trial conducted across 48 sites in 6 countries (N=2161; NCT04951856).
- Patients with high-risk STEMI or NSTEMI were randomized 1:1 to receive subcutaneous evolocumab 140 mg every 2 weeks for 1 year starting prior to PCI plus standard care (n=1087) or standard care alone (n=1074).
- The primary outcome of LDL-C <55 mg/dL and ≥50% reduction at 12 months was achieved in 792 of 970 patients (82%) with evolocumab vs 370 of 934 (40%) with standard care (adjusted OR, 5.54 [95% CI, 4.50-6.82]; P < .001).
- The main clinical endpoint of all-cause death or unplanned cardiovascular hospitalization at 12 months occurred in 159 of 1087 patients (14.6%) with evolocumab vs 165 of 1074 (15.4%) with standard care (adjusted OR, 0.94 [95% CI, 0.73-1.19]; P = .59).
Evidence details
What drove the result?
| Outcome | Evolocumab | Standard care |
|---|---|---|
| LDL-C <55 mg/dL + >=50% reduction at 12 months | 792/970 (82%) | 370/934 (40%) |
| Adjusted OR 5.54 (95% CI 4.50-6.82); P<.001 | ||
| Median LDL-C at 6 weeks | 16 mg/dL | 56 mg/dL |
| Rapid separation after in-lab initiation | ||
| All-cause death or unplanned CV hospitalization | 159/1087 (14.6%) | 165/1074 (15.4%) |
| Main clinical endpoint - adjusted OR 0.94 (0.73-1.19); P=.59 - no benefit at 1 year | ||
Limitations & tradeoffs
Design limitations
the primary endpoint is a lipid target, a surrogate rather than a clinical outcome, and LDL-C was assessable in only 970/1087 and 934/1074 patients.
Background therapy
control patients could receive PCSK9 inhibitors per guideline indication, diluting the contrast.
Structured PICO
Does evolocumab started before PCI improve LDL-C control and clinical outcomes at 1 year in patients with high-risk acute MI?
P
Population
2,161 adults with high-risk acute MI undergoing PCI, randomized to first-line evolocumab vs standard care, followed for 1 year.
I
Intervention
Evolocumab 140 mg subcutaneously every 2 weeks for 1 year (first injection before PCI) in addition to standard care (high-intensity oral lipid-lowering therapy).
C
Comparator
Standard care alone (high-intensity oral lipid-lowering therapy with optional PCSK9 inhibitor use per guideline indication).
O
Outcome
LDL-C less than 55 mg/dL and at least 50% reduction in LDL-C from baseline at 12 months.surrogate
Main Result
Odds Ratio: 5.54 (95% CI 4.5–6.82)
Absolute Event Rate: 82% vs 40%
p-value: p=<.001
First-line evolocumab administered before PCI in acute MI significantly improved LDL-C target achievement at 1 year but did not reduce all-cause death or unplanned cardiovascular hospitalization, arguing against acute pleiotropic clinical benefits.
Coverage & sources
Journal, society, and media accounts. Useful signal, not independent expert judgment.
Cite This Study
Montalescot et al. (2026) conducted an RCT in Acute myocardial infarction (n=2,161). Evolocumab vs. Standard care was evaluated on LDL-C less than 55 mg/dL and at least 50% reduction in LDL-C from baseline at 12 months (OR 5.54, 95% CI 4.50-6.82, p=<.001). First-line evolocumab before PCI for acute MI significantly improved LDL-C target achievement at 1 year (82% vs 40%; OR 5.54) but did not reduce all-cause death or cardiovascular hospitalization.